Shire Opens $1-Billion Plasma Manufacturing PlantBy
Shire has opened its more-than-$1-billion plasma manufacturing plant near Covington, Georgia.
The more than one-million-square-foot facility will add approximately 30% capacity to Shire’s internal plasma manufacturing network once fully operational. The plant has about 900 employees and is expected to have about 1,500 when it is fully operational.
The company makes immunoglobulin products at the plant to address primary immune deficiency disorders. In June 2018, the US Food and Drug Administration approved Shire’s submission for the new plasma manufacturing facility for producing Gammagard Liquid [immune globulin infusion (human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency.
Shire expects to make a second submission to the FDA in 2018 for development of its albumin therapy at the Georgia facility. Shire’s albumin therapy is primarily used as plasma-volume replacement therapy in immune disorders, trauma, and other critical conditions.
Baxter announced plans to build the facility in 2012. Shire subsequently acquired Baxalta, the biopharmaceutical operations of Baxter International, in 2016 for $32 billion. Earlier this year (May 2018), Shire reached an agreement on the terms of a recommended offer pursuant to which Takeda will acquire Shire in a $62-billion deal, pending shareholder and regulatory approvals.